April 8, 2024

MYTX-011: A pH-dependent anti-cMET ADC with increased payload delivery in vivo and potent activity against cMET-expressing tumors of various epithelial origins

American Association of Cancer Research (AACR) Annual Meeting

Deepak Kanojia, William Comb, William Israelsen, Federico Colombo, Lin Nie, Nimish Gera, Thomas Chittenden, Brian Fiske

October 13, 2023

MYTX-011 is a highly internalized ADC with anti-tumor activity across a spectrum of NSCLC preclinical models with various levels of cMET expression

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

William Comb, Deepak Kanojia, Federico Colombo, Vijay Ramesh, Nimish Gera, Thomas Chittenden, Brian Fiske

June 4, 2023

Phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate (ADC) MYTX-011 in subjects with non-small cell lung cancer

American Society of Clinical Oncology (ASCO) Annual Meeting

Alexander Spira, Melissa Johnson, George Blumenschein, Timothy Burns, Jonathan Thompson, Amit Deshpande, William Comb, Brian Fiske, Gilles Gallant, Rebecca Heist

April 18, 2023

MYTX-011: A novel cMET-targeting antibody drug conjugate (ADC) engineered to increase on-target uptake in and efficacy against cMETexpressing tumors

American Association of Cancer Research (AACR) Annual Meeting

Nimish Gera, Kyle Fitzgerald, Vijay Ramesh, Purvi Patel, Lena Kien, Deepak Kanojia, Simon Aoyama, Federico Colombo, Amit Deshpande, William Comb, Thomas Chittenden, Brian Fiske